by v4vapid, Steemit:
Dyncorp has many faces. The contractor is involved in an assortment of (above board) services worldwide, the vast majority of their business comes from large government contracts issued by US government agencies (USAID, State Department, Department of Defense).
In previous posts, I have highlighted how Dyncorp provided police personnel, police force training, prison construction and the contractor’s involvement in the CIA extraordinary rendition program. Much of my previous posts were focused on Haiti in particular, I intend on returning to the subject of Haiti in upcoming posts, but for now I want to discuss Dyncorp’s involvement in the development of vaccines.
Officially, Dyncorp is no longer in the business of researching and developing vaccines because it sold their subsidiary to another company CSC in 2003 and 2004.
In the not so distant past, Dyncorp created a joint venture with Porton International (UK) that became DynPort, later known as DVC (Dynport Vaccine Company LLC). Here is a brief history of DVC ownership from 1997 to 2017.
Today Dynport is owned by CSRA. CSRA headquarters is located about a 10 minute drive from Dyncorp International headquarters. Curiously enough, Dyncorp’s parent company Delta Tucker Holdings LLC is literally next door to CSRA in Falls Church, Virginia.
Dyncorp/Dynport’s involvement with vaccination programs is both eye opening and disturbing.
Here’s how the CSRA website describes DVC.
For those familiar with Dyncorp, it will come as no surprise that Dynport focussed on developing technologies for the military working closely with government agencies such as the Laboratory of Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Health (NIH) on vaccinations concerned with ‘biodefence’.
Here is a quick summary of some of the vaccines Dynport developed (or has been researching):
• Flu vaccine
• Small Pox vaccine
• Anthrax vaccine
• Tularemia vaccine
• Plague vaccine
• Swine Flu (H1N1) vaccine
• Nerve Agent vaccine (prophylactics)
Before teaming up with Dyncorp, Porton (UK) had created a US branch of their company know as BioPort. In the 1990s it had become one of a small minority of companies with the ability to produce an anthrax vaccine.
According to this October 2001 Salon.com article, The Anthrax Vaccine Scandal, BioPort executives were able to secure government contracts over more experienced companies even though their facilities were substandard, their finances were instable and they were accused of leveraging the close ties to the DoD and Pentagon of one of their executives to win favor.
In 1997, DynCorps partnered with the El-Hibris’ old company Porton International, to form DynPort Vaccine Company (DVC), just in time to beat out four other bids for a $322 million, 10-year contract.
Under the award, “DVC acts as a prime system contractor for the management of the existing stockpile of biological defense vaccines (except anthrax vaccine) and the advanced development, testing, production, FDA licensure, and storage of up to 18 new biological defense vaccines, including new vaccines against anthrax, small pox, plague, botulism and tularemia,” according to Pentagon spokesman Jim Turner.
The newly formed DynPort would continue to garner lucrative government contracts for development of Flu vaccines.
Please follow SGT Report on Twitter & help share the message.